1:23 PM
Oct 31, 2018
 |  BC Innovations  |  Distillery Therapeutics



Rat studies suggest M1 muscarinic receptor (CHRM1)-based chemogenetic inhibition of the prelimbic paraventricular thalamic nucleus pathway could help treat cocaine addiction. The system for chemogenetically inhibiting the pathway is initiated by bilateral injection into the prelimbic cortex of hM4Di, an inhibitory DREADD (Designer Receptors Exclusively Activated...

Read the full 211 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >